SCHEMBL3577408

SCHEMBL3577408

CNc1ccc(Cl)nc1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
KMT2A Q03164 3/20 0.40
GAA P10253 2/20 0.40
MEN1 O00255 2/20 0.40
MAP2K3 P46734 1/20 0.40
MAPK14 Q16539 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
KDM4E B2RXH2 1/20 0.39
GLA P06280 1/20 0.39
FABP3 P05413 1/20 0.38
FABP4 P15090 1/20 0.38
FABP5 Q01469 1/20 0.38
PIK3CA P42336 4/20 0.36
ACHE P22303 1/20 0.36
NAPRT Q6XQN6 1/20 0.36
MAPT P10636 2/20 0.36
PDE10A Q9Y233 1/20 0.36
HCAR3 P49019 1/20 0.36
ATM Q13315 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30473132 1.00 ALDH1A1 (0.40) ALDH1A1KMT2AGAAMEN1MAP2K3
SCHEMBL21666258 0.84 MAP2K3 (0.56) ALDH1A1KMT2AGAAMEN1MAP2K3
SCHEMBL11712622 0.82 MAPT (0.43) ALDH1A1KMT2AGAAMEN1GLA
Clopyralid SCHEMBL1698168 0.81 KMT2A (0.49) ALDH1A1KMT2AGAAMEN1KDM4E
SCHEMBL3576469 0.81 MAPT (0.44) ALDH1A1KMT2AGAAMEN1KDM4E
SCHEMBL3572829 0.79 KDM4C (0.41) ALDH1A1KMT2AMEN1MAP2K3MAPK14
SCHEMBL2339598 0.76 TDP1 (0.38) ALDH1A1KMT2AGAAMEN1KDM4C
SCHEMBL18084206 0.76 ALDH1A1 (0.33) ALDH1A1KMT2AGAAMEN1MAP2K3
SCHEMBL3586375 0.76 HCAR3 (0.42) ALDH1A1KMT2AGAAMEN1MAPT
Clopyralid SCHEMBL29371357 0.76 KMT2A (0.50) ALDH1A1KMT2AGAAMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US claimed
WO-2024054469-A1 ISOQUINOLONES AS PI3K INHIBITORS ONKURE, INC. (US) 2024-03-14 WO disclosed
WO-2023122777-A1 OXIME DERIVATIVES USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES, INC. (US) 2023-06-29 WO disclosed
WO-2023122777-A1 OXIME DERIVATIVES USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES, INC. (US) 2023-06-29 WO disclosed
WO-2023122772-A1 OXIME DERIVATIVES USEFUL AS T CELL ACTIVATORS GOSSAMER BIO SERVICES, INC. (US) 2023-06-29 WO disclosed
EP-1984340-B1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-06-27 EP disclosed
CN-101379036-B Anthranilamide/2-amino-heteroarene carboxamide derivatives HOFFMANN LA ROCHE 2011-06-01 CN disclosed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
CN-101379036-A Anthranilamide/2-amino-heteroarene carboxamide derivatives HOFFMANN LA ROCHE (CH) 2009-03-04 CN disclosed
EP-1984340-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-10-29 EP disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 US disclosed
WO-2007090752-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC ALDH1A1 1414/4885KMT2A 341/4885GAA 450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.